Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
SAN FRANCISCO, Dec. 06, 2016 -- BioQ Pharma Incorporated, a specialty pharmaceutical company, today announced the signing of a strategic distribution, supply and development agreement to commercialize three infusion pharmaceuticals in the United Kingdom and the Republic of Ireland with Galen Limited, a specialty pharmaceutical company marketing products within the UK, Ireland, Europe and the US in therapeutic areas such as pain management, gastroenterology and female health.
"We are delighted to partner with Galen Limited. Galen has a distinguished history in commercializing pharmaceutical products internationally. Their experience in launching innovative combination products into hospitals in the UK and Ireland will be invaluable to our collective commercial efforts moving forward,” said Josh Kriesel, President and CEO of BioQ Pharma.
About BioQ Pharma
BioQ Pharma Incorporated is a privately held specialty pharmaceutical company focused on developing and commercializing ready-to-use infusible pharmaceuticals. The Company's infusion platform is intended to address some of the most pressing unmet needs in drug infusion today: cost, medication error, sterility, efficiency, and patient quality of life. BioQ Pharma's vision is to set a new standard of care in the presentation and administration of infusible pharmaceuticals via the Company's proprietary unit-dose infusion systems that can be deployed quickly and conveniently at the point of care with one touch. The Company is ISO13485 certified. BioQ Pharma's commercial collaborators and strategic partners include Novartis' Sandoz unit, Cipla, Lee's Pharm, Lunatus, Galen Limited, and West Pharmaceutical Services.
Company Contact Information: Josh Kriesel President and CEO 415-336-6496 Ron Pauli Chief Financial Officer 415-889-7707 Walter Cleymans Vice President Europe Phone: +32 474 (053) 253 Media: Stephanie Carrington Integrated Corporate Relations, Inc. (ICR) 646-277-1282
